Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup |
| |
| Authors: | Nobuharu Tamaki Masayuki Kurosaki Yuka Takahashi Yoshie Itakura Sakura Kirino Kento Inada Koji Yamashita Shuhei Sekiguchi Yuka Hayakawa Leona Osawa Mayu Higuchi Kenta Takaura Chiaki Maeyashiki Shun Kaneko Yutaka Yasui Kaoru Tsuchiya Hiroyuki Nakanishi Jun Itakura Rohit Loomba Namiki Izumi |
| |
| Affiliation: | 1.Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan; (N.T.); (M.K.); (S.K.); (K.I.); (K.Y.); (S.S.); (Y.H.); (L.O.); (M.H.); (K.T.); (C.M.); (S.K.); (Y.Y.); (K.T.); (H.N.); (J.I.);2.Department of Medicine, Division of Gastroenterology and Hepatology, NAFLD Research Center, University of California San Diego, La Jolla, CA 92093, USA;3.Medical Examination Center, Musashino Red Cross Hospital, Tokyo 180-8610, Japan; (Y.T.); (Y.I.) |
| |
| Abstract: | Chronic liver disease is generally widespread, and a test for screening fibrotic subjects in a large population is needed. The ability of Wisteria floribunda agglutinin-positive mac-2 binding protein (WFA+-M2BP) to detect significant fibrosis was investigated in health checkup subjects in this research. Of 2021 health checkup subjects enrolled in this prospective cross-sectional study, those with WFA+-M2BP ≥ 1.0 were defined as high risk. Liver fibrosis was evaluated using magnetic resonance elastography (MRE) in subjects with high risk. The primary outcome was the positive predictive value (PPV) of WFA+-M2BP for significant fibrosis (liver stiffness ≥ 2.97 kPa by MRE). This trial was registered with the UMIN clinical trial registry, UMIN000036175. WFA+-M2BP ≥ 1.0 was observed in 5.3% of the 2021 subjects. The PPV for significant fibrosis with the threshold of WFA+-M2BP at ≥1.0, ≥1.1, ≥1.2, ≥1.3, ≥1.4, and ≥1.5 was 29.2%, 36.4%, 43.5%, 42.9%, 62.5%, and 71.4%, respectively. A WFA+-M2BP of 1.2 was selected as the optimal threshold for significant fibrosis among high-risk subjects, and the PPV, negative predictive value, sensitivity, and specificity for significant fibrosis were 43.5%, 84.0%, 71.4%, and 61.8%, respectively. WFA+-M2BP ≥ 1.2 was significantly associated with significant fibrosis, with an odds ratio (OR) of 4.04 (95% confidence interval (CI): 1.1–16, p = 0.04), but not FIB-4 ≥ 2.67 (OR: 2.40, 95%CI: 0.7–8.6, p-value = 0.2). In conclusion, WFA+-M2BP is associated with significant fibrosis and could narrow down potential subjects with liver fibrosis. The strategy of narrowing down fibrosis subjects using WFA+-M2BP may be used to screen for fibrotic subjects in a large population. |
| |
| Keywords: | WFA+-M2BP FIB-4 liver fibrosis screening |
|
|
